Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development
News
Broken String Biosciences strengthens senior leadership team to accelerate product development and commercialization
|
Global specialist in temperature-controlled logistics for life sciences, Biocair, has been awarded a 2023 EcoVadis silver medal for its overall achievements in sustainability. This is the second year that Biocair has achieved the silver medal from the esteemed sustainability rating provider.
External placement marks a key milestone in the development of Evonetix’s benchtop DNA synthesis technology, in preparation for customer use and commercialization
Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy
Alveron Pharma has successfully completed its first-in-human trial of OKL-1111, a new drug for the rapid treatment of intracranial haemorrhage associated with the use of anticoagulants or platelet inhibitors. The study was conducted at Hammersmith Medicines Research in London. OKL-1111 was well-tolerated in the trial with healthy human volunteers and showed no more adverse events above those in the placebo groups. Volunteers also received an anticoagulant and a pharmacodynamic effect was observed with OKL-1111 administration.
Press release
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
Edinburgh and Cambridge, UK, 29 September 2023 - Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB).
Cambridge, UK – 27 September 2023 – Eagle Genomics (“Eagle”) is pleased to announce it has raised additional financing of £3 million (USD $4 million) with continued participation from existing investors Environmental Technologies Fund, abrdn plc, and a consortium of investors headed by Granpool Innovative Investments, to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months.